Vanguard Group’s Sonoma Pharmaceuticals SNOA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $68.7K | Sell |
18,887
-1,986
| -10% | -$7.33K | ﹤0.01% | 4207 |
|
|
2025
Q3 | $81K | Buy |
+20,873
| New | +$82.1K | ﹤0.01% | 4249 |
|
|
2022
Q4 | – | Sell |
-1,701
| Closed | -$72K | – | 4553 |
|
|
2022
Q3 | $72K | Hold |
1,701
| – | – | ﹤0.01% | 4518 |
|
|
2022
Q2 | $99K | Buy |
1,701
+321
| +23% | +$20.6K | ﹤0.01% | 4551 |
|
|
2022
Q1 | $111K | Sell |
1,380
-1,357
| -50% | -$98.1K | ﹤0.01% | 4589 |
|
|
2021
Q4 | $250K | Buy |
2,737
+1,338
| +96% | +$143K | ﹤0.01% | 4535 |
|
|
2021
Q3 | $156K | Hold |
1,399
| – | – | ﹤0.01% | 4507 |
|
|
2021
Q2 | $205K | Buy |
1,399
+434
| +45% | +$68.1K | ﹤0.01% | 4367 |
|
|
2021
Q1 | $143K | Buy |
965
+397
| +70% | +$64.2K | ﹤0.01% | 4293 |
|
|
2020
Q4 | $83K | Buy |
568
+5
| +0.9% | +$760 | ﹤0.01% | 4154 |
|
|
2020
Q3 | $94K | Buy |
+563
| New | +$86.6K | ﹤0.01% | 4019 |
|
|
2019
Q2 | – | Sell |
-430
| Closed | -$73K | – | 4183 |
|
|
2019
Q1 | $73K | Buy |
430
+68
| +19% | +$10.3K | ﹤0.01% | 4035 |
|
|
2018
Q4 | $46K | Sell |
362
-209
| -37% | -$41.7K | ﹤0.01% | 4077 |
|
|
2018
Q3 | $150K | Sell |
571
-26
| -4% | -$9.45K | ﹤0.01% | 4036 |
|
|
2018
Q2 | $267K | Buy |
597
+34
| +6% | +$22.2K | ﹤0.01% | 3933 |
|
|
2018
Q1 | $373K | Buy |
563
+84
| +18% | +$69K | ﹤0.01% | 3842 |
|
|
2017
Q4 | $473K | Sell |
479
-1
| -0.2% | -$856 | ﹤0.01% | 3761 |
|
|
2017
Q3 | $451K | Sell |
480
-94
| -16% | -$102K | ﹤0.01% | 3774 |
|
|
2017
Q2 | $684K | Sell |
574
-116
| -17% | -$143K | ﹤0.01% | 3667 |
|
|
2017
Q1 | $890K | Buy |
690
+19
| +3% | +$22.1K | ﹤0.01% | 3613 |
|
|
2016
Q4 | $609K | Buy |
671
+71
| +12% | +$58.9K | ﹤0.01% | 3694 |
|
|
2016
Q3 | $468K | Buy |
600
+28
| +5% | +$21K | ﹤0.01% | 3768 |
|
|
2016
Q2 | $412K | Buy |
572
+37
| +7% | +$31.9K | ﹤0.01% | 3823 |
|
|
2016
Q1 | $460K | Buy |
535
+13
| +2% | +$12.1K | ﹤0.01% | 3808 |
|
|
2015
Q4 | $541K | Buy |
522
+6
| +1% | +$6.39K | ﹤0.01% | 3812 |
|
|
2015
Q3 | $600K | Buy |
516
+73
| +16% | +$86.5K | ﹤0.01% | 3796 |
|
|
2015
Q2 | $568K | Buy |
443
+14
| +3% | +$13.1K | ﹤0.01% | 3833 |
|
|
2015
Q1 | $324K | Buy |
429
+151
| +54% | +$128K | ﹤0.01% | 3923 |
|
|
2014
Q4 | $357K | Hold |
278
| – | – | ﹤0.01% | 3811 |
|
|
2014
Q3 | $587K | Buy |
278
+4
| +1% | +$9.3K | ﹤0.01% | 3675 |
|
|
2014
Q2 | $762K | Hold |
274
| – | – | ﹤0.01% | 3557 |
|
|
2014
Q1 | $929K | Buy |
274
+72
| +36% | +$245K | ﹤0.01% | 3479 |
|
|
2013
Q4 | $632K | Buy |
202
+74
| +58% | +$197K | ﹤0.01% | 3533 |
|
|
2013
Q3 | $318K | Hold |
128
| – | – | ﹤0.01% | 3624 |
|
|
2013
Q2 | $298K | Buy |
+128
| New | +$458K | ﹤0.01% | 3585 |
|
Other funds holding SNOA
DS
MCWS
GRP
TRCT
Vanguard Group's SNOA Position: Q4 2025 in Review
Vanguard Group reduced its Sonoma Pharmaceuticals (SNOA) stake by 9.5% in Q4 2025, selling an estimated $7.33K and leaving 18,887 shares worth $68.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4207.
Vanguard Group first reported a position in SNOA in Q2 2013 and has held it in 35 quarters since. The position peaked at $929K in Q1 2014. 16 funds tracked by Wall St. Rank hold SNOA as of Q4 2025.
- Vanguard Group held 18,887 shares of Sonoma Pharmaceuticals worth $68.7K as of Q4 2025.
- Vanguard Group sold 1,986 Sonoma Pharmaceuticals shares in Q4 2025, an estimated $7.33K.
- Sonoma Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4207 holding.
- Vanguard Group first reported a position in Sonoma Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- Vanguard Group's Sonoma Pharmaceuticals position peaked at $929K in Q1 2014.
- 16 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.